Studies Examining the Importance of Smoking After Being Diagnosed With Lung Cancer
Launched by DR KEIR LEWIS · Aug 31, 2010
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Smoking causes around 85% of lung cancer. Continued smoking after diagnosis probably worsens survival and increases treatment complications but prospective well-designed studies are lacking.
This project is an observational cohort study recording outcomes in smokers, never-smokers, and ex-smokers, using exhaled carbon monoxide to validate smoking status when they attend for further lung cancer clinics.
This project is unique, as every patient with a clinical diagnosis of lung cancer will have their smoking status biologically validated by a quick and easy test, and those enrolled in the s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinical diagnosis of lung cancer
- Exclusion Criteria:
- • refusal Consent
- • inability to provide exhaled CO
- • active psychiatric illness or substance misuse
- • concurrent malignancies of another type other than non-melanoma skin cancer
- • unable to travel for sessions with smoking cessation counsellor and / or outpatient visits from outset
- • WHO performance status 4
- • Life expectancy less than 6 weeks.
About Dr Keir Lewis
Dr. Keir Lewis is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical medicine and a focus on innovative therapeutic approaches, Dr. Lewis leads trials that prioritize patient safety and scientific integrity. His extensive experience in coordinating multi-disciplinary teams and navigating regulatory frameworks enables the efficient execution of trials across various therapeutic areas. Dr. Lewis is dedicated to fostering collaboration between researchers, healthcare professionals, and patients, ensuring that clinical findings translate into meaningful advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cardiff, Wales, United Kingdom
Llanelli, Wales, United Kingdom
Patients applied
Trial Officials
Keir E Lewis, MD
Principal Investigator
Hywel Dda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials